Canine atopic dermatitis is a chronic, relapsing inflammatory skin disease affecting up to 15% of the dog population, mirroring many aspects of human atopic dermatitis. Characterized by pruritus (itchiness), erythema, and recurrent skin infections, this condition significantly impacts the quality of life of both dogs and their owners.

Transpharmation offers two distinct models to support the development of dermatological therapeutics: a naturally occurring model of canine atopic dermatitis and an induced interleukin-31 (IL-31) pruritus model. These models enable the assessment of both long-term disease-modifying therapies and rapid-acting antipruritic agents.

Examples of endpoints:

  • •
    Pruritic behaviour activity scoring
  • •
    CADESI scoring
  • •
    Skin photographs
  • •
    Inflammatory biomarkers